IDEXX Laboratories, Inc. $IDXX Shares Purchased by Simon Quick Advisors LLC

Simon Quick Advisors LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.4% during the second quarter, Holdings Channel reports. The firm owned 1,152 shares of the company’s stock after buying an additional 295 shares during the period. Simon Quick Advisors LLC’s holdings in IDEXX Laboratories were worth $618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. Price T Rowe Associates Inc. MD raised its position in shares of IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after purchasing an additional 825,965 shares during the period. Select Equity Group L.P. acquired a new stake in IDEXX Laboratories in the first quarter worth $194,834,000. Nuveen LLC acquired a new stake in IDEXX Laboratories in the first quarter worth $179,784,000. Durable Capital Partners LP acquired a new stake in IDEXX Laboratories in the first quarter worth $153,180,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in IDEXX Laboratories by 37.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock worth $452,046,000 after buying an additional 290,551 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on IDXX. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Leerink Partners raised their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. BTIG Research raised their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Stifel Nicolaus upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and raised their price target for the company from $640.00 to $700.00 in a research note on Friday. Finally, Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $662.50.

IDEXX Laboratories Stock Up 0.2%

IDEXX Laboratories stock opened at $629.51 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a market cap of $50.36 billion, a price-to-earnings ratio of 52.42, a PEG ratio of 4.06 and a beta of 1.58. The company’s 50-day moving average price is $637.89 and its two-hundred day moving average price is $568.60.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business earned $2.44 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at $52,650,885.78. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 54,057 shares of company stock worth $34,293,468 in the last quarter. Company insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.